Skip to main content
. 2015 Nov 13;7(1):638–655. doi: 10.18632/oncotarget.6313

Figure 4. Antagonizing SET enhancing the effects of paclitaxel on NSCLC.

Figure 4

(A, B) Knockdown SET by shRNA significantly enhanced the pro-apoptotic effects paclitaxel. (A) The viability of A549 cells with or without SET knockdown after exposure to paclitaxel 10 nM for 48 hours. Bar: mean, error bar: S.D. (n = 6) (B) The percentage of apoptotic A549 cells with or without SET knockdown after exposure to paclitaxel 10 nM for 48 hours. Bar: mean, error bar: S.D. (n = 3) (C) The dose-dependent pro-apoptotic effects of paclitaxel combined with the novel SET antagonist, EMQA. Three different NSCLC cell lines exposed to the indicated treatments were analyzed by FACS (sub-G1 analysis). Bar: mean, error bar: S.D. (n = 3) (D) The combination index of three different NSCLC cell lines was determined by the results of sub-G1 analysis. (E) EMQA plus paclitaxel induced downregulation of p-Akt and apoptosis of NSCLC cells. Three different NSCLC cell lines exposed to EMQA 5 μM and/or paclitaxel 10 nM were analyzed by western blot. Representative western blot images of three identical experiments are shown.